Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this Application:

Listing of Claims:

1. (Original) A phospholipidic preparation consisting in a release system and a lexitropsin of general formula I



I (n=0,1)

in which R_1 is a functional group, preferably a basic one such as a simple or substituted amidine, a secondary or tertiary amine, a quaternary ammonium group, a simple or substituted guanidine, selected from:

$-C(NH)NH_2$, $-C(NH)NHR_3$, -NH2, NHR_3 $-N(R_3)_2$, $-NR_3R_4$, $-NH-C(NH)NH_2$, $-NH-C(NH)NHR_3$, $-N(CH_2)_4$, $N(R_3)_3+$

whereas R_2 represents an aliphatic, aromatic, or arylaliphatic acylic group, also if substituted with atomic groups containing one or more heteroatoms such as atoms of oxygen, nitrogen, or R_2 represents a sequence of one or more residues of 1-methyl-4-aminopyrrole-2-carboxylic acid, acylated or not acylated at the N-terminus, also terminating with a residue of 1-methyl-4-carboxamidopyrrole-2-carboxylic acid or with a residue of analogue aminoacids derived from an heterocycle different from pyrrole selected from furane, imidazole, thiophene, thiazole, or derived from benzene, pyridine, a diazine, pyrimidine, substituted or not at the terminal amino group with an acylic group, or containing, in place of the free or substituted amino group a carboxamido group, and R_3 or R_4 are equal or different lower alkyl groups C_1 to C_4,

the release system being a liposome, a micelle, a nanoparticle, a phospholipidic complex or a supramolecular phospholipidic structure able to incorporate a compound of general structure I in stable and reversible form.

2. (Original) A preparation according to claim 1, in form of multilamellar liposomes, composed of phosphatidyl glycerol (PG), phosphatidyl choline (PC) and cholesterol (C) containing an entrapped lexitropsin of formula I in an amount comprised in the range 1-10 percent of the mass of the liposome.

3. (Currently amended) A preparation according to claim 1, in the form of phospholipidic ~~vesicles~~ vesicles composed ~~by~~ of polyethyleneglycol phosphatidylethanolamine (PEGPE), PG and partially hydrogenated egg phosphatidyl choline (PHEPC) containing 1-10 % by weight of a lexitropsin.

4. (Original) A preparation according to any one of claims 1-3, comprising distamycin (II) in the form of an organic or inorganic salt, preferably as the hydrochloride, as



the active ingredient.

II

5. (Original) A preparation, according to any one of claims 1-3 comprising a compound X in the form of an organic or inorganic salt, preferably as the hydrochloride.



X

6. (Original) A topical preparation according to any one of claims 1-5, containing from 0.1 to 10% of active principle.

7. (Original) An Injectable preparation according to any one of claims 1-5 providing a dosage from 0.1 to 20 mg of a lexitropsin of general formula I, II or X per kg body weight.

8. (Original) The use of the preparations of claims 1-7 for the preparation of medicaments for the treatment of viral, or bacterial, or protozoarian infections.